tiprankstipranks
BeOne Medicines (ONC)
NASDAQ:ONC
US Market

BeOne Medicines (ONC) Stock Forecast & Price Target

858 Followers
See the Price Targets and Ratings of:

ONC Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
BeOne
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ONC Stock 12 Month Forecast

Average Price Target

$391.31
▲(25.91% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is $391.31 with a high forecast of $425.00 and a low forecast of $290.00. The average price target represents a 25.91% change from the last price of $310.79.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"244":"$244","335":"$335","426":"$426","289.5":"$289.5","380.5":"$380.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$425.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":391.3118181818182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$391.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$290.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[244,289.5,335,380.5,426],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,308.44,317.40615384615387,326.3723076923077,335.33846153846156,344.3046153846154,353.27076923076925,362.23692307692306,371.20307692307694,380.16923076923075,389.1353846153846,398.10153846153844,407.0676923076923,416.0338461538462,{"y":425,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,308.44,314.81475524475525,321.1895104895105,327.56426573426575,333.939020979021,340.31377622377624,346.68853146853144,353.06328671328674,359.43804195804194,365.8127972027972,372.18755244755243,378.5623076923077,384.93706293706293,{"y":391.3118181818182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,308.44,307.02153846153846,305.6030769230769,304.18461538461537,302.7661538461538,301.3476923076923,299.92923076923074,298.51076923076926,297.0923076923077,295.67384615384617,294.2553846153846,292.8369230769231,291.41846153846154,{"y":290,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":271.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":310.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":345,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.44,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$425.00Average Price Target$391.31Lowest Price Target$290.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on ONC
Truist Financial
Truist Financial
$310.79$412
Buy
32.57%
Upside
Reiterated
04/06/26
Truist Financial Remains a Buy on BeOne Medicines (ONC)
Wolfe Research Analyst forecast on ONC
Wolfe Research
Wolfe Research
$340
Buy
9.40%
Upside
Initiated
03/26/26
Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
Barclays Analyst forecast on ONC
Barclays
Barclays
$405
Buy
30.31%
Upside
Reiterated
03/18/26
Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)
Bernstein Analyst forecast on ONC
Bernstein
Bernstein
$412
Buy
32.57%
Upside
Reiterated
03/18/26
Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)
Jefferies
$290
Hold
-6.69%
Downside
Downgraded
03/15/26
BeOne Medicines downgraded to Hold from Buy at JefferiesBeOne Medicines downgraded to Hold from Buy at Jefferies
CMB International Securities Analyst forecast on ONC
CMB International Securities
CMB International Securities
$392.43
Buy
26.27%
Upside
Reiterated
03/02/26
Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)
Morgan Stanley Analyst forecast on ONC
Morgan Stanley
Morgan Stanley
$405$389
Buy
25.16%
Upside
Reiterated
02/27/26
BeOne Medicines (ONC) Gets a Buy from Morgan Stanley
TD Cowen Analyst forecast on ONC
TD Cowen
TD Cowen
$424
Buy
36.43%
Upside
Reiterated
02/26/26
Analysts Conflicted on These Healthcare Names: Ramsay Health Care (Other OTC: RMSYF) and BeOne Medicines (NASDAQ: ONC)
Guggenheim Analyst forecast on ONC
Guggenheim
Guggenheim
$400$410
Buy
31.92%
Upside
Reiterated
02/26/26
Guggenheim Keeps Their Buy Rating on BeOne Medicines (ONC)
RBC Capital Analyst forecast on ONC
RBC Capital
RBC Capital
$417$425
Buy
36.75%
Upside
Reiterated
02/26/26
BeOne Medicines (ONC) Receives a Buy from RBC Capital
Citi
$405
Buy
30.31%
Upside
Reiterated
01/13/26
Citi Sticks to Their Buy Rating for BeOne Medicines (ONC)
Bank of America Securities Analyst forecast on ONC
Bank of America Securities
Bank of America Securities
$389$402.2
Buy
29.41%
Upside
Reiterated
11/07/25
BeOne Medicines (ONC) Receives a Buy from Bank of America Securities
Citizens JMP Analyst forecast on ONC
Citizens JMP
Citizens JMP
$348$396
Buy
27.42%
Upside
Reiterated
11/07/25
BeOne Medicines price target raised to $396 from $348 at Citizens JMPBeOne Medicines price target raised to $396 from $348 at Citizens JMP
J.P. Morgan Analyst forecast on ONC
J.P. Morgan
J.P. Morgan
$345$385
Buy
23.88%
Upside
Reiterated
10/08/25
BeOne Medicines (ONC) Receives a Buy from J.P. Morgan
UBS Analyst forecast on ONC
Unknown Analyst
UBS
Not Ranked
UBS
$326$373
Buy
20.02%
Upside
Reiterated
08/07/25
UBS Sticks to Its Buy Rating for BeOne Medicines (ONC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on ONC
Truist Financial
Truist Financial
$310.79$412
Buy
32.57%
Upside
Reiterated
04/06/26
Truist Financial Remains a Buy on BeOne Medicines (ONC)
Wolfe Research Analyst forecast on ONC
Wolfe Research
Wolfe Research
$340
Buy
9.40%
Upside
Initiated
03/26/26
Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
Barclays Analyst forecast on ONC
Barclays
Barclays
$405
Buy
30.31%
Upside
Reiterated
03/18/26
Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)
Bernstein Analyst forecast on ONC
Bernstein
Bernstein
$412
Buy
32.57%
Upside
Reiterated
03/18/26
Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)
Jefferies
$290
Hold
-6.69%
Downside
Downgraded
03/15/26
BeOne Medicines downgraded to Hold from Buy at JefferiesBeOne Medicines downgraded to Hold from Buy at Jefferies
CMB International Securities Analyst forecast on ONC
CMB International Securities
CMB International Securities
$392.43
Buy
26.27%
Upside
Reiterated
03/02/26
Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)
Morgan Stanley Analyst forecast on ONC
Morgan Stanley
Morgan Stanley
$405$389
Buy
25.16%
Upside
Reiterated
02/27/26
BeOne Medicines (ONC) Gets a Buy from Morgan Stanley
TD Cowen Analyst forecast on ONC
TD Cowen
TD Cowen
$424
Buy
36.43%
Upside
Reiterated
02/26/26
Analysts Conflicted on These Healthcare Names: Ramsay Health Care (Other OTC: RMSYF) and BeOne Medicines (NASDAQ: ONC)
Guggenheim Analyst forecast on ONC
Guggenheim
Guggenheim
$400$410
Buy
31.92%
Upside
Reiterated
02/26/26
Guggenheim Keeps Their Buy Rating on BeOne Medicines (ONC)
RBC Capital Analyst forecast on ONC
RBC Capital
RBC Capital
$417$425
Buy
36.75%
Upside
Reiterated
02/26/26
BeOne Medicines (ONC) Receives a Buy from RBC Capital
Citi
$405
Buy
30.31%
Upside
Reiterated
01/13/26
Citi Sticks to Their Buy Rating for BeOne Medicines (ONC)
Bank of America Securities Analyst forecast on ONC
Bank of America Securities
Bank of America Securities
$389$402.2
Buy
29.41%
Upside
Reiterated
11/07/25
BeOne Medicines (ONC) Receives a Buy from Bank of America Securities
Citizens JMP Analyst forecast on ONC
Citizens JMP
Citizens JMP
$348$396
Buy
27.42%
Upside
Reiterated
11/07/25
BeOne Medicines price target raised to $396 from $348 at Citizens JMPBeOne Medicines price target raised to $396 from $348 at Citizens JMP
J.P. Morgan Analyst forecast on ONC
J.P. Morgan
J.P. Morgan
$345$385
Buy
23.88%
Upside
Reiterated
10/08/25
BeOne Medicines (ONC) Receives a Buy from J.P. Morgan
UBS Analyst forecast on ONC
Unknown Analyst
UBS
Not Ranked
UBS
$326$373
Buy
20.02%
Upside
Reiterated
08/07/25
UBS Sticks to Its Buy Rating for BeOne Medicines (ONC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines

3 Months
xxx
Success Rate
10/17 ratings generated profit
59%
Average Return
+4.26%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +4.26% per trade.
1 Year
Yaron WerberTD Cowen
Success Rate
29/35 ratings generated profit
83%
Average Return
+37.53%
Copying Yaron Werber's trades and holding each position for 1 Year would result in 82.86% of your transactions generating a profit, with an average return of +37.53% per trade.
2 Years
xxx
Success Rate
27/35 ratings generated profit
77%
Average Return
+54.33%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 77.14% of your transactions generating a profit, with an average return of +54.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ONC Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
20
23
18
20
15
Hold
1
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
23
18
21
16
In the current month, ONC has received 15 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ONC average Analyst price target in the past 3 months is 391.31.
Each month's total comprises the sum of three months' worth of ratings.

ONC Financial Forecast

ONC Earnings Forecast

Next quarter’s earnings estimate for ONC is $1.01 with a range of $0.29 to $2.22. The previous quarter’s EPS was $0.60. ONC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.
Next quarter’s earnings estimate for ONC is $1.01 with a range of $0.29 to $2.22. The previous quarter’s EPS was $0.60. ONC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.

ONC Sales Forecast

Next quarter’s sales forecast for ONC is $1.44B with a range of $1.34B to $1.54B. The previous quarter’s sales results were $1.50B. ONC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.
Next quarter’s sales forecast for ONC is $1.44B with a range of $1.34B to $1.54B. The previous quarter’s sales results were $1.50B. ONC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.

ONC Stock Forecast FAQ

What is ONC’s average 12-month price target, according to analysts?
Based on analyst ratings, BeOne Medicines’s 12-month average price target is 391.31.
    What is ONC’s upside potential, based on the analysts’ average price target?
    BeOne Medicines has 25.91% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ONC a Buy, Sell or Hold?
          BeOne Medicines has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is BeOne Medicines’s price target?
            The average price target for BeOne Medicines is 391.31. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $425.00 ,the lowest forecast is $290.00. The average price target represents 25.91% Increase from the current price of $310.79.
              What do analysts say about BeOne Medicines?
              BeOne Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of ONC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.